Impact of therapeutic interchange from pravastatin to lovastatin in a veterans affairs medical center

American Journal of Managed Care

Volumn 5, Issue 4, 1999, Pages 465-474

  Patel, Rachana J ^a   Gray, David R ^a   Pierce, Roger ^a   Jafari, Mahtab ^b  

^a VA LONG BEACH HEALTHCARE SYSTEM   (United States)

^b WESTERN UNIVERSITY OF HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; CHOLESTEROL; COLESTIPOL; FISH OIL; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NICOTINIC ACID; PRAVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; COST CONTROL; COST MINIMIZATION ANALYSIS; DRUG COST; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERCHOLESTEROLEMIA; LIPID BLOOD LEVEL; LIVER FUNCTION TEST; MALE; MUSCLE DISEASE; NEUROTOXICITY; OUTCOMES RESEARCH; PATIENT SATISFACTION; PRIORITY JOURNAL; QUALITY OF LIFE; SOLDIER; TREATMENT OUTCOME;

ANTICHOLESTEREMIC AGENTS; CALIFORNIA; COHORT STUDIES; COST SAVINGS; COST-BENEFIT ANALYSIS; FORMULARIES; HOSPITALS, VETERANS; HUMANS; LIPOPROTEINS, LDL; LOVASTATIN; OUTCOME ASSESSMENT (HEALTH CARE); PATIENT SATISFACTION; PHARMACY SERVICE, HOSPITAL; PHYSICIAN'S PRACTICE PATTERNS; PRAVASTATIN; PROSPECTIVE STUDIES; QUALITY OF LIFE; UNITED STATES;

EID: 0032930858     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Hsu I, Spinler SA, Johnson NE. Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia. Ann Pharmacother 1995;29:743-759.
2. McMillan K. Considerations in the formulary selection of hydroxymethylglutaryl-coenzyme A reductase inhibitors. Am J Health-Syst Pharm 1996;53:2206-2214.
3. Illingworth DR, Erkelens DW, Keller U, Thompson GR, Tikkanen MJ. Defined daily doses in relation to hypolipidaemic efficacy of lovastatin, pravastatin, and simvastatin. Lancet 1994;343:1554-1555.
4. The Lovastatin Pravastatin Study Group. A multicenter comparative trial of lovastatin and pravastatin in the treatment of hypercholesterolemia. Am J Cardiol 1993;71:810-815.
5. McPherson R. Comparison of the short-term efficacy and tolerability of lovastatin and pravastatin in the management of primary hypercholesterolemia. Clin Ther 1992;14:276-291.
6. The Post Coronary Artery Bypass Graft Trial Investigators. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous vein coronary-artery bypass grafts. N Engl J Med 1997;336:153-162.
7. Blankenhorn DH, Azen SP, Kramsch DM, et al. Coronary angiographic changes with lovastatin therapy. Ann Intern Med 1993;119:969-976.
8. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. JAMA 1998;278:1615-1622.
9. Holdford DA, Smith S. Improving the quality of outcomes research involving pharmaceutical services. Am J Health-Syst Pharm 1997;54:1434-1442.
10. Korman L, Boryshuk L. Replacing lovastatin with pravastatin: Effects on serum lipids and costs. Am J Health-Syst Pharm 1995;52:1078-1082.
11. Lovastatin package insert. West Point, PA: Merck & Co., Inc; March 1997.
12. Garnett WR. Interactions with hydroxymethylglutaryl-coenzyme A reductase inhibitors. Am J Health-Syst Pharm 1995;52:1639-1645.
13. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma without use of the preparative ultra-centrifuge. Clin Chem 1972;18:499-509.
14. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Summary of the second report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II). JAMA 1993;269:3015-3023.
15. Ware JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). Med Care 1992;30:473-483.
16. Flack MJ, Grimm RH. Hypertension/Lipid Form 5.1. Health Outcomes Institute, 1993.
17. Kong BW, Clive J, Kong SH. Quality of life as a vital clinical sign. J Hum Hypertens 1990;4:121-123.
18. Consumer Assessment of Health Plans Survey (CAHPS) 1.0 Survey and Reporting Kit. Rockville, MD: Agency for Health Care Policy & Research; 1998.
19. McDonald RC. An Introduction to Health Economics. Indianapolis, IN: Eli Lilly and Company; 1993:52.
20. Naranjo CA, Busto J, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-245.
21. American Medical Association. AMA policy on drug formularies and therapeutic interchange in inpatient and ambulatory patient care settings. Am J Hosp Pharm 1994;51:1808-1810.
22. Curtiss FR. Drug formularies provide a path to best care. Am J Hosp Pharm 1996;53:2201-2203.
23. American College of Physicians. Therapeutic substitution and formulary systems. Ann Intern Med 1990;113:160-163.
24. McKenny JM. Managing dyslipidemia with statins. Clin Pharm News Watch 1997;4:1-6.
25. Pearson TA, Laurora IM. Treatment success in patient sub-groups in the lipid treatment assessment project (L-TAP). [Abstact] Circulation 1997;96(suppl 1):1-66. Abstract.
26. Ware JE, Kosinski M, Keller SD. SF-36 Physical and Mental Health Summary Scales: A User's Manual. Boston, MA: The Health Institute; 1994.
27. Weir MR, Berger ML, Weeks ML, Liss CL, Santanello NC. Comparison of the effects on the quality of life and of the efficacy and tolerability of lovastatin versus pravastatin. Am J Cardiol 1996;77:475-479.
28. Mullins CD, Cooke CE, Cooke JL. Applications of pharmacoeconomics for managed care pharmacy. J Managed Care Pharm 1997;3:720-726.